Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Wuhan Hiteck Biological

PUBLIC STATUS
301-400 EMPLOYEES
300683 STOCK SYMBOL
$4.20 SHARE PRICE (As of Wednesday Closing)
Description

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Stock Exchange
SHE
Primary Office
  • Hite Science and Technology Park
  • Wuhan Economic Development Zone
  • Wuhan, Hubei 430056
  • China

+86 027 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Wuhan Hiteck Biological’s full profile, request a free trial.

Wuhan Hiteck Biological Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.69 - $9.11 $429M $4.15 $0.20 799K 103M

Wuhan Hiteck Biological Financials Summary

In Thousands,
USD
TTM
30-Sep-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 326,013 778,425
Revenue 89,500 111,019 115,747 108,190
EBITDA 19,479 24,612 27,684 16,285
Net Income 16,776 21,070 23,579 13,272
Total Assets 271,431 292,364 149,662 134,399
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Wuhan Hiteck Biological Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Wuhan Hiteck Biological‘s full profile, request access.

Request full access to PitchBook